Efficacy and Safety of Regdanvimab (CT-P59): A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial in Outpatients With Mild-to-Moderate Coronavirus Disease 2019
Open Forum Infectious Diseases (2022) - Comments
pubmed: 35295819  doi: 10.1093/ofid/ofac053  issn: 2328-8957 

Anca Streinu-Cercel, Oana Săndulescu, Liliana-Lucia Preotescu, Jin Yong Kim, Yeon-Sook Kim, Shinhye Cheon, Young Rock Jang, Sang Joon Lee, Sung Hyun Kim, Ilsung Chang, Jee Hye Suh, Seul Gi Lee, Mi Rim Kim, Da Rae Chung, Han Na Kim, Adrian Streinu-Cercel, Joong Sik Eom